BACKGROUND: Post-transplantation lymphoproliferative disorder (PTLD) is a group of life-threatening complications of organ transplantation, which occurs most frequently in pediatric patients. This retrospective study evaluates a single-institution experience of five cases of PTLD after living-donor liver transplantation (LDLT). PATIENTS AND METHOD: We reviewed the records of 78 pediatric patients (<18 years old) and 54 adult patients, who underwent LDLT between July 1991 and December 2009. RESULT: PTLD was diagnosed in five pediatric patients, yielding an overall incidence of 3.8%. There were no significant differences between the pediatric patients with and those without PTLD in terms of their age, sex, reason for transplantation, calcineurin inhibitor, Epstein-Barr virus (EBV) serostatus, ABO compatibility, lymphocyte cross-matching, or episodes of biopsy proven rejection. Two patients with abdominal lymphadenopathy and one with gastrointestinal PTLD responded to a reduction in immunosuppression. Treatment with rituximab was necessary for another gastrointestinal PTLD patient. Diffuse large-B-cell lymphoma was diagnosed in one patient with mediastinal and lung masses. This patient was treated with chemotherapy and rituximab, followed by surgical resection. All patients survived and no evidence of recurrence has been found since. CONCLUSION: Although PTLD is potentially life-threatening, it can be managed by appropriate and prompt treatment, with a good outcome.
BACKGROUND: Post-transplantation lymphoproliferative disorder (PTLD) is a group of life-threatening complications of organ transplantation, which occurs most frequently in pediatric patients. This retrospective study evaluates a single-institution experience of five cases of PTLD after living-donor liver transplantation (LDLT). PATIENTS AND METHOD: We reviewed the records of 78 pediatric patients (<18 years old) and 54 adult patients, who underwent LDLT between July 1991 and December 2009. RESULT: PTLD was diagnosed in five pediatric patients, yielding an overall incidence of 3.8%. There were no significant differences between the pediatric patients with and those without PTLD in terms of their age, sex, reason for transplantation, calcineurin inhibitor, Epstein-Barr virus (EBV) serostatus, ABO compatibility, lymphocyte cross-matching, or episodes of biopsy proven rejection. Two patients with abdominal lymphadenopathy and one with gastrointestinal PTLD responded to a reduction in immunosuppression. Treatment with rituximab was necessary for another gastrointestinal PTLDpatient. Diffuse large-B-cell lymphoma was diagnosed in one patient with mediastinal and lung masses. This patient was treated with chemotherapy and rituximab, followed by surgical resection. All patients survived and no evidence of recurrence has been found since. CONCLUSION: Although PTLD is potentially life-threatening, it can be managed by appropriate and prompt treatment, with a good outcome.
Authors: S H K Oertel; E Verschuuren; P Reinke; K Zeidler; M Papp-Váry; N Babel; R U Trappe; S Jonas; M Hummel; I Anagnostopoulos; B Dörken; H B Riess Journal: Am J Transplant Date: 2005-12 Impact factor: 8.086
Authors: C V Paya; J J Fung; M A Nalesnik; E Kieff; M Green; G Gores; T M Habermann; P H Wiesner; J L Swinnen; E S Woodle; J S Bromberg Journal: Transplantation Date: 1999-11-27 Impact factor: 4.939
Authors: Timothy C Lee; Barbara Savoldo; Neal R Barshes; Cliona M Rooney; Helen E Heslop; Adrian P Gee; Yvette Caldwell; Jaymee D Scott; John A Goss Journal: Clin Transplant Date: 2006 May-Jun Impact factor: 2.863
Authors: Vahakn B Shahinian; Norman Muirhead; Anthony M Jevnikar; Stephen H Leckie; Anand K Khakhar; Patrick P Luke; Kamilia S Rizkalla; David J Hollomby; Andrew A House Journal: Transplantation Date: 2003-03-27 Impact factor: 4.939
Authors: Barbara Savoldo; Cliona M Rooney; Ruben E Quiros-Tejeira; Yvette Caldwell; Hans-Joachim Wagner; Timothy Lee; Milton J Finegold; Gianpietro Dotti; Helen E Heslop; John A Goss Journal: Am J Transplant Date: 2005-03 Impact factor: 8.086
Authors: Stephen L Guthery; James E Heubi; John C Bucuvalas; Thomas G Gross; Frederick C Ryckman; Maria H Alonso; William F Balistreri; Richard W Hornung Journal: Transplantation Date: 2003-04-15 Impact factor: 4.939
Authors: Afshin A Khan; Bassam N Estfan; Anirudh Yalamanchali; Djibril Niang; Erica C Savage; Clifton G Fulmer; Hailey L Gosnell; Jamak Modaresi Esfeh Journal: World J Clin Oncol Date: 2022-06-24
Authors: Rohit Bishnoi; Ravneet Bajwa; Aaron J Franke; William Paul Skelton; Yu Wang; Niraj M Patel; William Birdsall Slayton; Fei Zou; Nam H Dang Journal: Exp Hematol Oncol Date: 2017-09-29